This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago.
ALK gene rearrangements are found in around 5 percent of lung cancer tumors and are more common in people with lung cancer who never smoked. Crizotinib is an oral drug that was found to inhibit the effects of the ALK gene and to stop or reverse tumor growth.
In this phase II trial, researchers followed 901 patients for safety and 261 patients for tumor response; all of the patients had at least one prior chemotherapy treatment for their lung cancer. The overall response rate to crizotinib treatment was 60 percent and the median progression free survival (PFS) was eight months, confirming prior findings that crizotinib shrinks ALK-positive lung cancers and demonstrates a high PFS rate.
¡°This trial demonstrates that we have a good opportunity to shrink cancers and improve symptoms for patients with this subtype of lung cancer,¡± said Gregory Riely, MD, PhD, lead author of the study and a medical oncologist at Memorial Sloan-Kettering Cancer Center in New York who specializes in treating lung cancer. ¡°This confirms the results of prior studies and further shows that crizotinib can reduce the effects of symptoms, thereby improving the quality of life for thousands of patients who are diagnosed with this late-stage lung cancer. This study confirms that crizotinib is the standard of care for patients with ALK positive lung cancer.¡±
The abstract, ¡°Results of a Global Phase II Study with Crizotinib in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC),¡± will be presented during the Plenary Session at 12:30 p.m., Central time on September 7, 2012. To speak with Gregory Riely, MD, PhD, please contact Michelle Kirkwood or Nicole Napoli on September 6-8, 2012, in the press office at the Chicago Marriott Downtown Magnificent Mile at 312-595-3188.Abstract 4
G. J. Riely1, T. L. Evans2, R. Salgia3, S. I. Ou4, S. N. Gettinger5, G. A. Otterson6, S. Lanzalone7, A. Polli8, A. T. Shaw9, 1Memorial Sloan-Kettering Cancer Center, New York, 2University of Pennsylvania, Philadelphia, 3University of Chicago, Chicago, 4University of California at Irvine, Irvine, Calif., 5Yale University School of Medicine, New Haven, Conn., 6The Ohio State University, Columbus, Ohio, 7Pfizer Italy Srl, Milan, Italy, 8Pfizer Inc., Milan, Italy, 9Massachusetts General Hospital Cancer Center, Boston
Purpose/Objective(s): Approximately 3-5% of NSCLC harbors ALK gene rearrangements. Crizotinib is a first-in-class, oral, small-molecule competitive ALK inhibitor with anti-MET activity.
Materials/Methods: PROFILE 1005 is an ongoing global, multicenter, open-label, single-arm, phase II study evaluating the safety and efficacy of crizotinib (250 mg BID in 3-week cycles) in patients with advanced ALK-positive NSCLC who progressed after ¡Ý1 chemotherapy for recurrent/advanced/metastatic disease. Tumor response was evaluated by RECIST 1.1 every 6 weeks.
Results: As of June 2011, 439 patients were evaluable for safety and 255 patients for tumor response. Median age was 53 years. The majority of patients were female (53%), never smokers (65%), and had adenocarcinoma (92%), ECOG PS 0-1 (83%) and ¡Ý2 prior chemotherapy regimens (85%). Among patients evaluable for efficacy, median treatment duration was 25 weeks (77% of patients still ongoing). ORR was 53% (95% CI: 47-60), disease control rate at 12 weeks was 85% (95% CI: 80-89), median duration of response was 43 weeks (96% CI 36-50) and median PFS was 8.5 months (95% CI: 6.2-9.9). The most frequent treatment-related AEs were visual effects (50%), nausea (46%), vomiting (39%), and diarrhea (35%), mostly grade 1-2. 29 patients (6.6%) had treatment-related SAEs, including dyspnea and pneumonitis (4 patients each; 0.9%), and febrile neutropenia and renal cyst (2 patients each; 0.5%).
Conclusions: Crizotinib demonstrated a high response rate and PFS, and a favorable tolerability profile. These results provide strong evidence for crizotinib as a standard of care for advanced ALK-positive NSCLC.
Author Disclosure Block: G.J. Riely: E. Research Grant; BMS, Pfizer, Merck, GSK, Infinity. G. Consultant; Chugai, Tragara, Ariad, Daiichi, Abbott. T.L. Evans: None. R. Salgia: None. S.I. Ou: E. Research Grant; Pfizer. F. Honoraria; Pfizer. G. Consultant; Pfizer. S.N. Gettinger: E. Research Grant; Pfizer. G.A. Otterson: E. Research Grant; Pfizer, Genentech, Tragara, Amgen, Pharmacyclics. G. Consultant; Genentech, Abraxis. S. Lanzalone: A. Employee; Pfizer. K. Stock; Pfizer. A. Polli: A. Employee; Pfizer. K. Stock; Pfizer. A.T. Shaw: E. Research Grant; Novartis, Astra Zeneca, Pfizer, Ariad. F. Honoraria; Novartis, Millenium. G. Consultant; Pfizer, Ariad, Chugai, Daiichi-Sankyo.Media Contacts
Michelle Kirkwood | EurekAlert!
Correct connections are crucial
26.06.2017 | Charité - Universitätsmedizin Berlin
One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...
19.06.2017 | Event News
13.06.2017 | Event News
13.06.2017 | Event News
27.06.2017 | Power and Electrical Engineering
27.06.2017 | Information Technology
27.06.2017 | Physics and Astronomy